NCT04377295View on ClinicalTrials.gov

Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 30, 2012

Primary Completion Date

October 1, 2019

Study Completion Date

October 30, 2019

Conditions
Radiation Maculopathy
Interventions
DRUG

Ranibizumab 0.5Mg/0.05Ml Oph Inj

All patients received one monthly intravitreal injection of Ranibizumab (0.5 mg/0.05 ml) through the pars plana under aseptic conditions until maximum visual acuity was achieved and there was no sign of macular edema at optical coherence tomography

All Listed Sponsors
lead

Federico II University

OTHER

NCT04377295 - Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab | Biotech Hunter | Biotech Hunter